Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 3Breast Neoplasms 2Thymoma 1Hypoxia 1Hereditary Sensory and Autonomic Neuropathies 1Extensive Stage Small Cell Lung Cancer 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 12Nivolumab 4fludarabine 3Gemcitabine 3Drug Therapy 3Cisplatin 3spartalizumab 2budigalimab 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zenocutuzumab 1venetoclax 1ulixertinib 1tocilizumab 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1neratinib 1milademetan 1margetuximab 1erdafitinib 1entrectinib 1cobimetinib 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × NVP-BKM120 × Thoracic × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡